Council Decision (EU) 2026/1070 of 5 May 2026 on the position to be taken on behalf of the European Union within the CETA Joint Committee established under the Comprehensive Economic and Trade Agreement (CETA) between Canada, of the one part, and the European Union and its Member States, of the other part, as regards the inclusion of active pharmaceutical ingredients as medicinal products or drugs listed in paragraph 2 of Annex 1 to the Protocol on the mutual recognition of the compliance and enforcement programme regarding good manufacturing practices for pharmaceutical products